严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
2019-20冠状病毒爆发
2019年冠状病毒病(COVID-19)
临床试验
免疫
免疫原性
作者
Ana Sara Cordeiro,María J. Alonso
出处
期刊:Pharmaceutical patent analyst
[Newlands Press Ltd]
日期:2016-01-01
卷期号:5 (1): 49-73
被引量:19
摘要
The field of vaccination is moving from the use of attenuated or inactivated pathogens to safer but less immunogenic protein and peptide antigens, which require stronger adjuvant compositions. Antigen delivery carriers appear to play an important role in vaccine development, providing not only antigen protection and controlled release but also an intrinsic adjuvant potential. Among them, carriers based on polymers and lipids are the most representative ones. Patent applications in this area have disclosed, either the design and preparation methods for new biocompatible antigen delivery systems or the application of the previously developed systems for the delivery of novel antigens. Some of them have also reported the use of these technologies for modern therapeutic vaccination approaches.
科研通智能强力驱动
Strongly Powered by AbleSci AI